COPD Patient Types
For many COPD patients, consider twice-daily BROVANA® (arformoterol tartrate)
You can review various COPD patient types to see how nebulized therapy with BROVANA® (arformoterol tartrate) Inhalation Solution may benefit your COPD patients. There is also an overview of the GOLD guidelines and their recommendations for treating moderate to very severe COPD with long-acting bronchodilators.1
Click below to review 4 COPD patient types:
CAROL >
Have a low peak inspiratory flow rate (PIFR)
As with other inhaled beta2-agonists, BROVANA® (arformoterol tartrate) Inhalation Solution can produce paradoxical bronchospasm that may be life-threatening.
LUKE >
Using a nebulized, short-acting bronchodilator ≥4 times daily
BROVANA® (arformoterol tartrate) Inhalation Solution is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers.
Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.
RUTH >
Have coordination or dexterity limitations
NORMAN >
Could benefit from adding a long-acting bronchodilator to their current tiotropium therapy
BROVANA® (arformoterol tartrate) Inhalation Solution should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists.
Not actual COPD patients